Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Digestive Risks in 55 Placebo Trials: Extra Cases per 1,000

Pooling 106,395 participants, gallstones rose by about 2 cases per 1,000 and the review estimated about 4 additional reflux cases per 1,000.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
Extra cases per 1,000 people treatedgallstones2 more in 1,000reflux4 more in 1,00055 trials, 106,395 participants

The review estimated about four additional diagnoses of gastroesophageal reflux disease per 1,000 people treated, compared with placebo [1]. That figure describes the difference in risk, rather than the total number of people who developed reflux.

What was pooled

Our GLP-1 side-effect guide covers common symptoms such as nausea. This review searched five databases for placebo-controlled randomized trials that reported specific gastrointestinal and biliary events in type 2 diabetes, overweight or obesity, and fatty liver disease. It included 55 trials and 106,395 participants [1].

Two things went up

Gallstones. The risk ratio was 1.46, 95% CI 1.09 to 1.97, which the authors translate as about 2 extra cases per 1,000 people treated. Reflux. The risk ratio was 2.19, 95% CI 1.48 to 3.25, or about 4 extra cases per 1,000.

The 46% relative increase in gallstone risk corresponded to about two extra cases per 1,000 people at the baseline risk used in this review. Our gallbladder risk guide explains why estimates differ across outcomes and studies. A person's baseline risk affects the absolute difference.

What the review found for other outcomes

The authors judged that treatment probably had little or no effect on the other outcomes they studied, including pancreatitis, bowel obstruction, gastrointestinal bleeding and gastroparesis.

Rare events can be hard to measure even across many trials. The pooled results leave uncertainty about how much risk changes for some outcomes.

What to check about follow-up care

Our guide to advertised and billed prices explains why a medication quote and the cost of clinical care can differ. Ask who handles new symptoms during treatment and whether follow-up visits carry a separate charge.

Frequently asked

How much does gallstone risk actually rise?
The pooled risk ratio was 1.46, 95% CI 1.09 to 1.97, which the review states as roughly 2 extra cases per 1,000 people treated. Both framings describe the same result.
Does it cause pancreatitis?
The review judged that GLP-1 treatment probably had little or no effect on pancreatitis risk in the trials it examined. Rare events can still be difficult to estimate.
Is the risk higher at higher doses?
It looked that way and the difference did not reach statistical significance. The same applies to trials in obesity and to the agents producing the most weight loss, so treat it as a hypothesis rather than a dosing rule.
What should I budget for?
Ask what the quoted price covers and what you would pay separately for follow-up visits or testing.

Sources

  1. [1] Chiang CH, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis Gastroenterology. PMID 40499738

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence